Prantik Das
Overview
Explore the profile of Prantik Das including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
168
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nugent K, Das P, Ford D, Sabharwal A, Perna C, Dallas N, et al.
Adv Radiat Oncol
. 2024 Sep;
9(9):101574.
PMID: 39224488
Purpose: To report acute and late bowel, urinary, and sexual dysfunction patient-reported outcome measures, among patients with localized prostate cancer who underwent stereotactic magnetic resonance-guided daily adaptive radiation therapy (SMART)....
2.
Moreno-Olmedo E, Sabharwal A, Das P, Dallas N, Ford D, Perna C, et al.
Cancers (Basel)
. 2024 Aug;
16(15).
PMID: 39123406
Renal cell cancer (RCC) has traditionally been considered radioresistant. Because of this, conventional radiotherapy (RT) has been predominantly relegated to the palliation of symptomatic metastatic disease. The implementation of stereotactic...
3.
Ghose A, Lapitan P, Apte V, Ghosh A, Kandala A, Basu S, et al.
Curr Oncol Rep
. 2024 Apr;
26(6):633-646.
PMID: 38652426
Purpose Of Review: Our review delves into the progress across urological malignancies and discusses ongoing challenges and future directions in antibody-drug conjugate (ADC) development, emphasising their transformative potential in cancer...
4.
Das P, Booth A, Donaldson R, Berfeld N, Nordstrom B, Carroll R, et al.
Clin Genitourin Cancer
. 2024 Apr;
22(3):102081.
PMID: 38641444
Background And Objective: Considering the rapidly evolving treatment landscape of renal cell carcinoma (RCC), recent descriptions of the RCC population in the UK are lacking, as are real-world data on...
5.
Birtle A, Jones R, Chester J, Lewis R, Biscombe K, Johnson M, et al.
J Clin Oncol
. 2024 Feb;
42(13):1466-1471.
PMID: 38350047
JCO POUT was a phase III, randomized, open-label trial, including 261 patients with muscle-invasive or lymph node-positive, nonmetastatic upper tract urothelial cancer (UTUC) randomly assigned after radical nephroureterectomy to platinum-based...
6.
Attard G, Murphy L, Clarke N, Sachdeva A, Jones C, Hoyle A, et al.
Lancet Oncol
. 2023 May;
24(5):443-456.
PMID: 37142371
Background: Abiraterone acetate plus prednisolone (herein referred to as abiraterone) or enzalutamide added at the start of androgen deprivation therapy improves outcomes for patients with metastatic prostate cancer. Here, we...
7.
Drabble J, Das P, George B, Camilleri P, Morris A
Med Dosim
. 2022 Jul;
47(4):334-341.
PMID: 35907693
This study aims to calculate planning target volume (PTV) margins for the prostate and seminal vesicles (SVs) from the use of magnetic resonance-guided radiation therapy (MRgRT). And whether nonisotropic PTV...
8.
James N, Ingleby F, Clarke N, Amos C, Attard G, Brawley C, et al.
JNCI Cancer Spectr
. 2022 Jul;
6(4).
PMID: 35877084
Background: STAMPEDE previously reported adding upfront docetaxel improved overall survival for prostate cancer patients starting long-term androgen deprivation therapy. We report long-term results for non-metastatic patients using, as primary outcome,...
9.
Payne H, Jain S, Peedell C, Edwards A, Thomas J, Das P, et al.
BMJ Open
. 2022 Jul;
12(7):e060506.
PMID: 35858729
Objectives: To identify consensus on patient prioritisation for rectal hydrogel spacer use during radiation therapy for the treatment of prostate cancer in the UK. Design: Delphi study consisting of two...
10.
Das P, Taylor S, Price J, Jones M, Martin-Fernandez C, Ali A, et al.
BJUI Compass
. 2022 Apr;
1(1):21-31.
PMID: 35474912
Background: Abiraterone acetate combined with Prednisone/Prednisolone (AA+P) and Enzalutamide (ENZ) have proven survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC) in chemotherapy-naïve and prior chemotherapy patients. There have...